These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 14678081)

  • 1. Inhibitory effects of SR 49059 on oxytocin-and vasopressin-induced uterine contractions in non-pregnant women.
    Steinwall M; Bossmar T; Gaud C; Akerlund M
    Acta Obstet Gynecol Scand; 2004 Jan; 83(1):12-8. PubMed ID: 14678081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions.
    Bossmar T; Brouard R; Döberl A; Akerlund M
    Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers.
    Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F
    Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-mediated uterine effects of vasopressin and oxytocin in nonpregnant women.
    Bossmar T; Akerlund M; Szamatowicz J; Laudanski T; Fantoni G; Maggi M
    Br J Obstet Gynaecol; 1995 Nov; 102(11):907-12. PubMed ID: 8534628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women.
    Akerlund M; Bossmar T; Brouard R; Kostrzewska A; Laudanski T; Lemancewicz A; Serradeil-Le Gal C; Steinwall M
    Br J Obstet Gynaecol; 1999 Oct; 106(10):1047-53. PubMed ID: 10519430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of relcovaptan (SR 49059), an orally active vasopressin V1a receptor antagonist, on uterine contractions in preterm labor.
    Steinwall M; Bossmar T; Brouard R; Laudanski T; Olofsson P; Urban R; Wolff K; Le-Fur G; Akerlund M
    Gynecol Endocrinol; 2005 Feb; 20(2):104-9. PubMed ID: 15823830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
    Chan WY; Wo NC; Manning M
    Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors.
    Chen YL; Shepherd C; Spinelli W; Lai FM
    Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrauterine pressure, ischemia markers, and experienced pain during administration of a vasopressin V1a receptor antagonist in spontaneous and vasopressin-induced dysmenorrhea.
    Liedman R; Grant L; Igidbashian S; James I; McLeod A; Skillern L; Akerlund M
    Acta Obstet Gynecol Scand; 2006; 85(2):207-11. PubMed ID: 16532916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ONO-8815Ly, an EP2 agonist that markedly inhibits uterine contractions in women.
    Steinwall M; Akerlund M; Bossmar T; Nishii M; Wright M
    BJOG; 2004 Feb; 111(2):120-4. PubMed ID: 14723748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of oxytocin and vasopressin V1a antagonists in the treatment of preterm labour and primary dysmenorrhoea.
    Akerlund M; Melin P; Maggi M
    Adv Exp Med Biol; 1995; 395():595-600. PubMed ID: 8714023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uterine blood flow and myometrial activity at menstruation, and the action of vasopressin and a synthetic antagonist.
    Hauksson A; Akerlund M; Melin P
    Br J Obstet Gynaecol; 1988 Sep; 95(9):898-904. PubMed ID: 3191063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxytocin and vasopressin V(1A) receptors as new therapeutic targets in assisted reproduction.
    Pierzynski P
    Reprod Biomed Online; 2011 Jan; 22(1):9-16. PubMed ID: 21130036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans.
    Weber R; Pechère-Bertschi A; Hayoz D; Gerc V; Brouard R; Lahmy JP; Brunner HR; Burnier M
    Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
    Serradeil-Le Gal C; Herbert JM; Delisee C; Schaeffer P; Raufaste D; Garcia C; Dol F; Marty E; Maffrand JP; Le Fur G
    Am J Physiol; 1995 Jan; 268(1 Pt 2):H404-10. PubMed ID: 7840290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibromyomas and uterine contractions.
    Szamatowicz J; Laudanski T; Bulkszas B; Akerlund M
    Acta Obstet Gynecol Scand; 1997 Nov; 76(10):973-6. PubMed ID: 9435739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacology of (2S,4Z)-N-[(2S)-2-hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2'-methyl[1,1'-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a new potent and selective nonpeptide antagonist of the oxytocin receptor.
    Cirillo R; Gillio Tos E; Schwarz MK; Quattropani A; Scheer A; Missotten M; Dorbais J; Nichols A; Borrelli F; Giachetti C; Golzio L; Marinelli P; Thomas RJ; Chevillard C; Laurent F; Portet K; Barberis C; Chollet A
    J Pharmacol Exp Ther; 2003 Jul; 306(1):253-61. PubMed ID: 12660315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium.
    Bossmar T; Rasmussen T; Akerlund M
    Acta Obstet Gynecol Scand; 1996 Jul; 75(6):516-9. PubMed ID: 8693925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of SR49059, an orally active V1a vasopressin receptor antagonist, in the prevention of dysmenorrhoea.
    Brouard R; Bossmar T; Fournié-Lloret D; Chassard D; Akerlund M
    BJOG; 2000 May; 107(5):614-9. PubMed ID: 10826575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of oxytocin and vasopressin in the pathophysiology of preterm labor and primary dysmenorrhea.
    Akerlund M
    Prog Brain Res; 2002; 139():359-65. PubMed ID: 12436949
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.